Although several studies have discussed the potential benefits of SGLT2 inhibitors in COVID-19 patients (Chatterjee, 2020; Koufakis et al., 2020), the use of SGLT2 inhibitors was not beyond criticism. Here, SLC5A2 is linked to COVID-19.